ACE inhibitors have revolutionised the treatment of chronic heart failure; however, as is often the case with drug treatment, we are remarkably ignorant of exactly how they work. Understanding the mechanisms involved is of fundamental importance because it is a major goal of pharmacological research to produce more specific drugs that act on the mechanism producing clinical benefit while having no eVect on the mechanisms producing adverse effects. This ideal scenario seems to be a possibility if we substitute angiotensin II receptor antagonist drugs for ACE inhibitors. The rather optimistic idea behind this is that most if not all of the benefits of ACE inhibitors are because of angiotensin II suppression while the main adverse eVect of ACE inhibitors (cough) is caused by bradykinin accumulation. How has practice lived up to this theory?
A third issue of pharmacological importance is that angiotensin II can be formed by routes other than angiotensin converting enzyme. Enzymes such as chymase, cathepsin G, and CAGE (chymostatin sensitive angiotensin II generating enzyme) seem able to generate angiotensin II by non-ACE routes. 3 We do not really know how big a contribution these non-ACE enzymes make to the production of angiotensin II but clearly ACE inhibitors will not prevent angiotensin II being formed from non-ACE enzymes, whereas AT 1 receptor antagonists will block the eVect of angiotensin II, irrespective of which enzyme produced the angiotensin II. In this way, AT 1 receptor antagonists are likely to be able to block the eVects of angiotensin II more eVectively than ACE inhibitors can (table 1) .
AT 1 receptor antagonists in hypertension
These theoretical benefits have led the pharmaceutical industry to develop a large number of AT 1 receptor antagonist drugs. These have initially been developed for the treatment of essential hypertension where they have generally fulfilled their promise of being safe, eYcacious, and well tolerated. They appear to be better tolerated than other first line antihypertensive agents, including ACE inhibitors. In particular, the promise of their producing less cough than ACE inhibitors seems to have been fulfilled. 4 Indeed the incidence of all side eVects of AT 1 receptor antagonist appears to be much the same as placebo, which cannot be said for any other class of antihypertensive drug. As you would expect, drug companies marketing AT 1 receptor antagonists are now trying to distinguish between the various agents. In hypertension, this is likely to focus on diVerences in antihypertensive eYcacy, particularly diVerences in blood pressure control at trough drug concentrations. We are likely to be bombarded in the near future with data on this subject, but the jury is still out on whether any diVerences really exist.
AT 1 receptor agonists in heart failure There are two major constraints in clinical trials with AT 1 receptor antagonists in heart failure. The first is ethical in that ACE inhibitors cannot be withheld from patients for long because of their undoubted clinical benefit. This means that clinical trials with AT 1 receptor antagonists cannot be done in the traditional way comparing the new drug with placebo. The second constraint is a genuine uncertainty about whether the future place of AT 1 receptor antagonists in heart failure will be as a substitute for ACE inhibitors or as an addition. This question remains wide open. Until recently, clinical trials with AT 1 receptor antagonists in heart failure have in general shown that they exert the expected haemodynamic and neurohormonal eVects. DeKock et al showed that single doses of losartan caused vasodilatation and reduced aldosterone and noradrenaline compared with placebo. 5 Crozier et al found that, compared with placebo, chronic losartan treatment (12 weeks) reduced pulmonary capillary wedge pressure, systemic vascular resistance, blood pressure, and even heart rate, while cardiac index rose. 6 In long term studies comparing losartan with enalapril, both drugs seemed equivalent in terms of exercise capacity, clinical status, neurohormonal activation and adverse eVects. 7 8 Therefore, losartan as the prototype AT 1 receptor antagonist appeared to be as good as an ACE inhibitor, but there were no clear signs in heart failure that it might be any better. All that changed in early 1997 with publication of the ELITE trial results. 4 
Glossary

ELITE TRIAL
The ELITE study was not intended to be a mortality study, rather it was a study of the safety of losartan in elderly patients with chronic heart failure. Therefore, we should view the mortality data from the ELITE study with scepticism. Nevertheless, the surprising finding was that losartan (50 mg/day) produced a 46% reduction (p = 0.035) in all cause mortality compared with captopril (50 mg three times daily). This diVerence was mainly because of a decrease in sudden deaths in the losartan group. Interestingly, losartan was also better tolerated than captopril, especially with regard to cough. Indeed, significantly more patients withdraw from captopril than from losartan (21% v 12%, p = 0.002). The benefits of losartan on all cause mortality could not be attributed to the greater withdrawal rate in the captopril group as there was an even greater mortality benefit (57% reduction) in those who remained on their study drug.
These results are, to say the least, intriguing. A second study is ongoing to see whether it can confirm this beneficial eVect; ELITE II is a much larger trial with mortality as the primary end point. However, a recent unpublished study was unable to confirm the ELITE results.
Assuming that the ELITE results are genuine, why should losartan perform better than captopril? Clearly it could be related to pharmacology, which has been discussed above (table 1) . The first possibility is that ACE inhibitors allow angiotensin II to be formed from non-ACE pathways. Data from the CONSENSUS and SOLVD studies show that patients who have high plasma concentrations of angiotensin II despite enalapril treatment have a worse prognosis than those with suppressed angiotensin II. 9 10 This could explain the ELITE results because patients with high angiotensin II concentrations despite ACE inhibitor treatment should benefit from blockade of the angiotensin II receptors, which would eVectively neutralise the harmful eVects of reactivated angiotensin II.
The second possibility is that the bradykinin produced by ACE inhibitors might be harmful rather than beneficial. Several studies attest to the fact that bradykinin can release noradrenaline, which could arrhythmogenic. 11 12 Such a mechanism might explain why losartan produced fewer sudden deaths than captopril in ELITE-that is, captopril increased bradykinin, which increased arrhythmogenic catecholamines.
Until these issues are resolved by ELITE II and other studies, what significance should the practising doctor attach to the original ELITE results. In view of all the beneficial trial data with ACE inhibitors, it would clearly be inappropriate to change large numbers of patients from ACE inhibitors to AT 1 receptor antagonists on the basis of one small trial; however, even a pessimist looking at the ELITE results is likely to think that AT 1 receptor antagonists may be equivalent to ACE inhibitors regarding mortality. The upshot is that patients who are truly intolerant of ACE inhibitors (especially because of cough) may well be able to get an equivalent mortality benefit if they are switched from an ACE inhibitor to an AT 1 receptor antagonist. This is a fairly small group of patients for whom hydralazine plus isosorbide dinitrate is a good alternative, with better documented mortality benefits. Nevertheless, it may be that heart failure patients who complain of ACE inhibitor cough should be switched to an AT 1 receptor antagonist rather than persuaded to continue the ACE inhibitor and tolerate the cough. The other tangible eVect of the ELITE results is to engender a sense of hopeful expectation that this new class of drugs may well be as important a step in the management of heart failure as were ACE inhibitors.
Conclusions
The prospects are therefore good for AT 1 receptor antagonists, but there are more questions about these agents than there are answers. Many trials are underway that will provide these answers and that will tell us whether AT 1 receptor antagonists are likely to eclipse ACE inhibitors or whether they will turn out to be another blind therapeutic alley. The ELITE study suggests that the former is more likely than the latter.
